Technical Data
DPT (Dermatopontin, Tyrosine-rich Acidic Matrix Protein, TRAMP)
Dermatopontin, is a widely expressed noncollagenous protein component of the extracellular matrix (1,2). Mature human Dermatopontin shares 96%, 92%, and 92% aa sequence identity with bovine, mouse, and rat Dermatopontin, respectively. It is a 22kD molecule that is tyrosine sulfated but not glycosylated (3,4). Dermatopontin contains three disulfide bonded loop structures that enclose conserved hexapeptide motifs (5). It accelerates collagen fibril formation in vitro, and Dermatopontin deficient mice exhibit altered collagen matrix deposition and organization (6-8). Dermatopontin is downregulated in fibrotic growths such as leiomyoma and scar tissue (9,10). It binds both TGF-b and the proteoglycan decorin, interactions that can increase the bioavailability of TGF-b (11,12). Dermatopontin promotes bone mineralization under the control of the vitamin D receptor and inhibits BMP-2 effects on osteoblast precursors (13,14).

Suitable for use in Western Blot. Other applications not tested.

Recommended Dilution:
Western Blot: 1ug/ml
Optimal dilutions to be determined by the researcher.

Storage and Stability:
Lyophilized powder may be stored at -20C. Stable for 12 months at -20C. Reconstitute with PBS. Aliquot to avoid repeated freezing and thawing. Store at -20C. Reconstituted product is stable for 12 months at -20C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
PabIgGAffinity Purified
100ug-20CBlue IceHumanSheep
Not determined
Recombinant corresponding to aa19-201 from human Dermatopontin expressed in NSO cells (AAH33736).
Purified by immunoaffinity chromatography.
Supplied as a lyophilized powder in PBS, trehalose. Reconstitute with sterile PBS to 200ug/ml.
Recognizes human Dermatopontin. Species sequence homology: Recombinant mouse Dermatopontin (50%).
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Okamoto, O. and S. Fujiwara (2006) Connect. Tissue Res. 47:177. 2. Superti-Furga, A. et al. (1993) Genomics 17:463. 3. Forbes, E.G. et al. (1994) FEBS Lett. 351:433. 4. Cronshaw, A.D. et al. (1993) Matrix 13:255. 5. Neame, P.J. et al. (1989) J. Biol. Chem. 264:5474. 6. MacBeath, J.R.E. et al. (1993) J. Biol. Chem. 268:19826. 7. Takeda, U. et al. (2002) J. Invest. Dermatol. 119:678. 8. Cooper, L.J. et al. (2006) Invest. Opthalmol. Vis. Sci. 47:3303. 9. Catherino, W.H. et al. (2004) Genes Chromosomes Cancer 40:204. 10. Kuroda, K. et al. (1999) J. Invest. Dermatol. 112:706. 11. Okamoto, O. et al. (1996) J. Biochem. 119:106. 12. Okamoto, O. et al. (1999) Biochem. J. 337:537. 13. Pochampally, R.R. et al. (2007) J. Bone Miner. Res. 22:1338. 14. Behnam, K. et al. (2006) Connect. Tissue Res. 47:271.